Healthcare Industry News: colorectal cancer
News Release - April 24, 2008
SpectraScience Secures Distribution for WavSTAT(R) System in Czech RepublicSAN DIEGO, April 24 (HSMN NewsFeed) -- SpectraScience, Inc. (OTC Bulletin Board: SCIE ), a San Diego based medical device company, today announced that it has established a distribution partnership in the Czech market through the Almeda Company, a Prague-based firm specializing in medical device sales in the region for almost two decades.
Michel Vaudry, SpectraScience's Director of International Sales commented that "the Czech Republic is attractive on many fronts as an entry point into the European market for our WavSTAT System, both for its aging population and its established $1.2 billion medical device market. In addition, the Czech Republic has one of the highest incidences of colorectal cancer in the world. We are exploring additions to our export sales team in other European countries such as Italy, Germany and France."
Almeda's Director Ales Zavorka stated that "the WavSTAT System fills a significant gap in our product offering to the Czech market which has a particularly high incidence of colon cancer. Other drivers for the product in the market are its ease of use and performance, both of which are extremely appealing to the physician community."
Key Benefits to the WavSTAT Optical Biopsy System
-- Leaves polyps on site if they are not pre-cancerous
-- Ability for physician to perform physical biopsy at exactly same site as optical biopsy
-- Aids physician during colon cancer surgery
-- Complementary to NBI and Smart Pill
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-KSB and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-KSB and other documents.
About SpectraScience, Inc.
SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provides the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMAŽ cervical imaging technology has received FDA approval as an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.